US company trials double chin drug

A drug, that aims to reduce the appearance of a double chins, is undergoing trials in the US. ATX-101 has been developed by California-based medical company Kythera Biopharmaceuticals and contains deoxycholic acid, a naturally occurring molecule that helps the body break down fat.

The drug is in late-stage clinical trials and is yet to be approved by the FDA. The injections have been tested on more than 1,600 patients, with over 90% reporting a long-term reduction of fat under the chin. The company said that the drug was tolerated well by most patients, and that the most common side effects experienced were pain around the treatment area, numbness, bruising, swelling and redness. The FDA is set to complete its review of the drug on May 13.

A drug, that aims to reduce the appearance of a double chins, is undergoing trials in the US. ATX-101 has been developed by California-based medical company Kythera Biopharmaceuticals and contains deoxycholic acid, a naturally occurring molecule that helps the body break down fat.

The drug is in late-stage clinical trials and is yet to be approved by the FDA. The injections have been tested on more than 1,600 patients, with over 90% reporting a long-term reduction of fat under the chin. The company said that the drug was tolerated well by most patients, and that the most common side effects experienced were pain around the treatment area, numbness, bruising, swelling and redness. The FDA is set to complete its review of the drug on May 13.